Dr. Randi Isaacs' upcoming presentation at the KidneyCAN 7th Annual Kidney Cancer Research Summit highlights Werewolf's innovation in conditionally activated therapeutics, which could enhance ...

ILKN421H is a novel lipid nanoparticle (LNP)-formulated mRNA encoding a non-alpha HSA–IL-2v fusion protein and dominantly expressed in lymphoid organs after IV injection. ILKN421H selectively expanded ...

Researchers at Peking Union Medical College Hospital have mapped out why pairing two well-known cancer drugs can turn “sleepy” immune cells back into tumor killers. In a new Perspective published ...

In terms of safety, among participants receiving monotherapy and combination therapy, 19 (27.9%) and 26 (35.6%) reported treatment-related adverse events (TRAEs) of Grade 3 or higher, respectively.

Detailed price information for Medicenna Therapeutics Corp (MDNAF) from The Globe and Mail including charting and trades.